All In Biotech

Drug Trial Radar · NCT00077584

Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With Scleroderma

A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients With Systemic Sclerosis

Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

188

Actual

Start

Oct 2003

Primary completion

Mar 2005

Study completion May 2005

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Feb 11, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In an earlier clinical trial, RAPIDS-1, conducted in scleroderma patients with or without digital ulcers at baseline, bosentan significantly reduced the number of new digital ulcers versus placebo. The purpose of the present trial (RAPIDS-2) is to evaluate the prevention and healing effects of bosentan versus placebo on digital ulcers over a 24-week treatment period.

Conditions

  • Digital Ulcers
  • Systemic Sclerosis

Interventions

  • Bosentan 62.5 mgDrug

    Oral tablets containing 62.5 mg of bosentan

  • Bosentan 125 mgDrug

    Oral tablets containing 125 mg of bosentan

  • PlaceboDrug

    Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to complete healing of the cardinal ulcer (CU) up to Week 24 in patients with CU healing maintained for 12 weeksTime frame: 24 weeks
  2. Total number of new digital ulcers per patient up to Week 24Time frame: 24 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.